9 unknown, 7 recruiting, 5 completed, 5 not yet recruiting. 17 Phase 2, 7 Phase 1, 4 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Biliary Tract Carcinoma: new trials by email Literature Review of Biliary Tract Carcinoma trials Research Report on Biliary Tract Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers DISP-10 - Colorectal Cancer, Gastric Adenocarcinoma | Phase 1 | Recruiting | Dispatch Biotherapeutics | 66 | 2026-04-13 | 2026-10-05 |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma ZG005, Tislelizumab, Gemcitabine - Biliary Tract Carcinoma | Phase 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 60 | 2025-12-02 | 2026-05-01 |
| A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC Recaticimab and Adebrelimab, GP chemotherapy - Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 39 | 2025-07-10 | 2025-07-14 |
| Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC Irinotecan Liposome, Capecitabine - Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Sir Run Run Shaw Hospital | 76 | 2024-11-14 | 2024-11-21 |
| Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma Pemigatinib and Durvalumab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 38 | 2024-08-01 | 2024-07-31 |
| Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma irinotecan hydrochloride liposome injection, Capecitabine, Lenvatinib - Biliary Tract Carcinoma | Not applicable | Not yet recruiting | Yunpeng Liu | 30 | 2024-07-01 | 2024-06-18 |
| Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma irinotecan hydrochloride liposome injection, Capecitabine - Biliary Tract Carcinoma | Phase 2 | Unknown | Ba Yi | 20 | 2024-06-30 | 2024-05-28 |
| Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma ID-RFA and Radiotherapy - Biliary Tract Carcinoma, Radiotherapy | Not applicable | Recruiting | National Cancer Center, Korea | 53 | 2024-04-01 | 2025-06-19 |
| A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）, Anti-PD-1 monoclonal antibody, Oxaliplatin and Capecitabine - Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma | Not applicable | Unknown | Zhejiang Cancer Hospital | 120 | 2024-03-20 | 2024-08-27 |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Active not recruiting | Nataliya Uboha | 33 | 2024-03-08 | 2026-08-17 |
| SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma SBRT Sequential Surufatinib Combined With Immunotherapy - Biliary Tract Carcinoma | Phase 2 | Suspended | Zhejiang Cancer Hospital | 34 | 2024-02-01 | 2024-10-15 |
| Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction Cryobiopsy catheter - Biliary Tract Carcinoma, Biliary Obstruction | Not applicable | Unknown | Brno University Hospital | 20 | 2023-06-01 | 2023-09-21 |
| Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma Gemcitabine, S1, Tislelizumab - Biliary Tract Carcinoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2023-04-30 | 2023-04-20 |
| Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN. - Biliary Tract Carcinoma | Unknown | Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University | 300 | 2023-03-30 | 2023-12-18 | |
| GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab - Biliary Tract Carcinoma | Phase 2 | Recruiting | Fudan University | 93 | 2022-10-18 | 2026-01-14 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib) - Breast Cancer, Biliary Tract Carcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 460 | 2021-10-18 | 2026-10-13 |
| A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Abemaciclib - Biliary Tract Carcinoma | Phase 2 | Terminated | Milton S. Hershey Medical Center | 4 | 2021-09-24 | 2024-10-08 |
Showing 20 of 32. Sign in to see all of them.
Cholangiocarcinoma (5) · Gallbladder Neoplasms (5) · Bile Duct Neoplasms (3) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Recurrence (3) · Adenocarcinoma Of Esophagus (2) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Transitional Cell (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2)
Neoplasms by Site (14) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Neoplasms (12) · Carcinoma (8) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Adenocarcinoma (7) · Biliary Tract Diseases (6) · Biliary Tract Neoplasms (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Gastrointestinal Diseases (6) · Urogenital Diseases (6) · Gallbladder Diseases (5)
Gemcitabine (11) · Cisplatin (9) · Oxaliplatin (6) · Capecitabine (5) · tislelizumab (4) · pembrolizumab (3) · donafenib (2) · AZD 6244 (1) · AZD5305 (1) · Antineoplastic Protocols (1) · Bevacizumab (1) · Brachytherapy (1) · Fluorouracil (1) · Genetic Testing (1) · Immunotherapy (1)
Fudan University (3) · Merck Sharp & Dohme LLC (3) · Eli Lilly and Company (2) · Mayo Clinic (2) · University Health Network, Toronto (2) · Zhejiang Cancer Hospital (2) · AstraZeneca (1) · Ba Yi (1) · Brno University Hospital (1) · Dispatch Biotherapeutics (1) · Eastern Hepatobiliary Surgery Hospital (1) · IDEAYA Biosciences (1) · Milton S. Hershey Medical Center (1) · Nataliya Uboha (1) · National Cancer Center, Korea (1)
China (16) · United States (8) · South Korea (4) · Canada (3) · Japan (3) · Australia (2) · Belgium (2) · Italy (2) · Netherlands (2) · Spain (2) · Taiwan (2) · Thailand (2) · United Kingdom (2) · Argentina (1) · Brazil (1)
Jennifer Knox, M.D. (2) · Edward Chan, MD (1) · Jason Wu (1) · Jewel Samadder, M.D. (1) · Jia Fan (1) · Lu Wang, M.D. (1) · Luying Liu, M.D. (1) · Mingyu Chen, Ph.D (1) · Nataliya Uboha, MD, PhD (1) · Nelson Yee, MD, Ph.D (1) · Roxana S. Dronca, MD (1) · Sang Myung Woo, M.D (1) · Xiujuan Qu (1)
PMID 42176183, PMID 22425920, PMID 24995270, PMID 26851032, PMID 28958907, PMID 29108980, PMID 29342492, PMID 30439965, PMID 30541334, PMID 30808323, PMID 30861593, PMID 33381458, PMID 34499416, PMID 36460085, PMID 37075781, PMID 38661512, PMID 39206260, PMID 39392424, PMID 40154623, PMID 40268484, PMID 40445839, PMID 40835595
2019 (1), 2023 (1)